Meningococcal Disease | BEXSERO (Meningococcal Group B Vaccine) HCP

KNOW THE RISK: MENINGOCOCCAL DISEASE CAN PROGRESS FAST AND BE FATAL¹

An uncommon but serious bacterial infection caused by Neisseria meningitidis^1,2

Symptoms can progress to death in as few as 24 hours^1,3

Of those who contract meningococcal disease, between 10% and 15% die from complications despite appropriate antibiotic treatment²

About 11% to 19% of survivors suffer permanent sequelae, such as seizures/neurological problems, loss of limbs, kidney damage, hearing loss, skin scarring, and brain damage^1,4,5

INDICATION & IMPORTANT SAFETY INFO

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO

BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

KNOW THE RISK: MENINGOCOCCAL DISEASE CAN PROGRESS FAST AND BE FATAL¹

According to CDC, serogroup B caused the majority of all US meningococcal cases in patients 16-23 years of age from 2015 to 2019⁶

The MenB vaccination rate among adolescents is low⁷

Follow the CDC recommendation

See the impact of MenB

KNOW THE RISK: MENINGOCOCCAL DISEASE CAN PROGRESS FAST AND BE FATAL1

According to CDC, serogroup B caused the majority of all US meningococcal cases in patients 16-23 years of age from 2015 to 20196

The MenB vaccination rate among adolescents is low7

Follow the CDC recommendation

See the impact of MenB

KNOW THE RISK: MENINGOCOCCAL DISEASE CAN PROGRESS FAST AND BE FATAL¹

According to CDC, serogroup B caused the majority of all US meningococcal cases in patients 16-23 years of age from 2015 to 2019⁶

The MenB vaccination rate among adolescents is low⁷